PGZ Stock Overview
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Healius Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.74 |
| 52 Week High | AU$1.97 |
| 52 Week Low | AU$0.67 |
| Beta | 0.65 |
| 1 Month Change | -1.97% |
| 3 Month Change | -10.78% |
| 1 Year Change | -58.15% |
| 3 Year Change | -71.56% |
| 5 Year Change | -61.32% |
| Change since IPO | -70.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| PGZ | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 4.9% | 5.4% | 1.7% |
| 1Y | -58.1% | 0.6% | 2.3% |
Return vs Industry: PGZ underperformed the German Healthcare industry which returned 1.9% over the past year.
Return vs Market: PGZ underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| PGZ volatility | |
|---|---|
| PGZ Average Weekly Movement | 7.4% |
| Healthcare Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PGZ has not had significant price volatility in the past 3 months.
Volatility Over Time: PGZ's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 10,500 | Paul Anderson | www.healius.com.au |
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services.
Healius Limited Fundamentals Summary
| PGZ fundamental statistics | |
|---|---|
| Market cap | €551.35m |
| Earnings (TTM) | -€597.80m |
| Revenue (TTM) | €1.03b |
0.5x
P/S Ratio-0.9x
P/E RatioIs PGZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PGZ income statement (TTM) | |
|---|---|
| Revenue | AU$1.69b |
| Cost of Revenue | AU$1.16b |
| Gross Profit | AU$532.00m |
| Other Expenses | AU$1.52b |
| Earnings | -AU$984.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.36 |
| Gross Margin | 31.45% |
| Net Profit Margin | -58.17% |
| Debt/Equity Ratio | 39.3% |
How did PGZ perform over the long term?
See historical performance and comparison